Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?

被引：5

作者：

Facchinetti, Francesco ^{[1
]}

Majori, Maria ^{[2
]}

Sabato, Mariangela ^{[3
]}

Gnetti, Letizia ^{[4
]}

Tiseo, Marcello ^{[1
,5
]}

机构：

[1] Univ Hosp Parma, Dept Gen & Specialist Med, Med Oncol Unit, I-43126 Parma, Italy

[2] Univ Hosp Parma, Dept Gen & Specialist Med, Pulmonol & Thorac Endoscopy Unit, I-43126 Parma, Italy

[3] Univ Hosp Parma, Dept Radiol, I-43126 Parma, Italy

[4] Univ Hosp Parma, Pathol Sect, Diagnost Dept, I-43126 Parma, Italy

[5] Univ Parma, Dept Med & Surg, I-43126 Parma, Italy

来源：

IMMUNOTHERAPY | 2019年 / 11卷 / 03期

关键词：

central location; hemoptysis; non-small-cell lung cancer (NSCLC); PD-L1; pembrolizumab; tumor shrinkage; RANDOMIZED PHASE-II; BEVACIZUMAB; DOCETAXEL; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; MANAGEMENT; HEMORRHAGE; NIVOLUMAB; THERAPY;

D O I：

10.2217/imt-2018-0136

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A patient diagnosed with centrally located advanced lung adenocarcinoma with signs of large vessels infiltration, strongly expressing PD-L1, was candidate to first-line pembrolizumab. He had not complained of any bleeding manifestation before immunotherapy. 5 days after the first dose of pembrolizumab, the patient experienced massive, fatal hemoptysis. Given the central localization of the tumor and the strong PD-L1 expression, a contribution of rapid disease shrinkage is envisaged in determining the fatal hemorrhagic event. An attentive clinical attitude should be dedicated in centrally located and vessel-infiltrating tumors strongly expressing PD-L1 and candidate to anti-PD-1/PD-L1 agents.

引用

页码：161 / 166

页数：6

共 31 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC [J].

Artal-Cortes, Angel ;

Felices-Lobera, Pilar ;

Marquez-Medina, Diego .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) :E76-E77

[3] Targeting immune checkpoints in non small cell lung cancer [J].

Bianco, Andrea ;

Malapelle, Umberto ;

Rocco, Danilo ;

Perrotta, Fabio ;

Mazzarella, Gennaro .

CURRENT OPINION IN PHARMACOLOGY, 2018, 40 :46-50

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

[7] Elements of cancer immunity and the cancer-immune set point [J].

Chen, Daniel S. ;

Mellman, Ira .

NATURE, 2017, 541 (7637) :321-330

[8] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[9] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

[10] Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study [J].

Gettinger, Scott ;

Horn, Leora ;

Jackman, David ;

Spigel, David ;

Antonia, Scott ;

Hellmann, Matthew ;

Powderly, John ;

Heist, Rebecca ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Geese, William J. ;

Yoon, Dennis ;

Li, Ang ;

Brahmer, Julie .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1675-+

← 1 2 3 4 →